|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2003-12-25
|
|
pubmed:abstractText |
The restricted expression of the surface glycoprotein prostrate-specific membrane antigen (PSMA) to normal prostate tissue, primary and metastatic prostate cancer (PCa), and the neovasculature of various nonprostatic epithelial malignancies has enabled targeting strategies for PCa treatment using anti-PSMA antibodies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6357-62
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14695135-Aged,
pubmed-meshheading:14695135-Aged, 80 and over,
pubmed-meshheading:14695135-Antigens, Surface,
pubmed-meshheading:14695135-Autoradiography,
pubmed-meshheading:14695135-Cytoplasm,
pubmed-meshheading:14695135-Glutamate Carboxypeptidase II,
pubmed-meshheading:14695135-Humans,
pubmed-meshheading:14695135-Immunohistochemistry,
pubmed-meshheading:14695135-In Situ Hybridization,
pubmed-meshheading:14695135-Male,
pubmed-meshheading:14695135-Middle Aged,
pubmed-meshheading:14695135-Multivariate Analysis,
pubmed-meshheading:14695135-Neoplasm Metastasis,
pubmed-meshheading:14695135-Prognosis,
pubmed-meshheading:14695135-Prostatic Neoplasms,
pubmed-meshheading:14695135-RNA, Messenger,
pubmed-meshheading:14695135-Recurrence,
pubmed-meshheading:14695135-Time Factors
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
|
|
pubmed:affiliation |
Departments of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York 12208, USA. rossj@mail.amc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
